Chemotherapy-Induced Nausea and Vomiting

Main Article Content

Surachai Leksuwankun
Piyanuch Wonanan


Chemotherapy-induced nausea and vomiting (CINV) is one of the most common side effects of cancer treatment. There are many receptors involved in the CINV pathophysiology, such as 5-hydroxytryptamine-3 (5-HT3) receptor, neurokinin-1 (NK-1) receptor, and dopamine receptor. As rapid progress in research and drug development, there are many effective drugs available for CINV including 5-HT3 receptor antagonists, NK-1 receptor antagonists, dexamethasone, and dopamine antagonists. In clinical practice, the antiemetic regimen used for CINV prophylaxis is primarily based on emetogenic risk and their mechanisms of action. This article aims at guiding healthcare providers on the appropriate management of CINV.        


Download data is not yet available.

Article Details

Review Articles


Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, et al. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer. 2015 Jan;23(1):263-72.

Koth SM, Kolesar J.New options and controversies in the management of chemotherapy-induced nausea and vomiting.Am J Health Syst Pharm. 2017 Jun 1;74(11):812-9.

Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice:a community hospital-based study.Support Care Cancer.2012 Jan; 20(1):107-17.

Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer. 2011 Jun;19(6):843-51.

Ballatori E, Roila F, Ruggeri B, Porrozzi S, Iannopollo M, Soru G, et al. The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer. 2007 Jan;15(1):31-8.

Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983 May;25 (Suppl 1):1-7.

Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017 Apr;23(14 Suppl):S259-S65.

Shankar A, Roy S, Malik A, Julka PK, Rath GK. Prevention of chemotherapy-induced nausea and vomiting in cancer patients. Asian Pac J Cancer Prev. 2015;16(15):6207-13.

Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017 Jun; 28(6):1260-7.

Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2014 May;47(5):839-48.e4.

Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. Patient-related risk factors for chemotherapy-induced nausea and vomiting:a systematic review.Front Pharmacol. 2020 Apr;11:329.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016 Sep;27(Suppl 5):v119-v33.

Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem Rev. 2009 Jul; 109(7):3158-99.

Rapoport BL. Delayed chemotherapy-induced nausea and vomiting: patho-genesis, incidence, and current management. Front Pharmacol. 2017 Jan 30;8:19.

Bayo J, Fonseca PJ, Hernando S, Servitja S, Calvo A, Falagan S, et al. Chemo-therapy-induced nausea and vomiting: pathophysiology and therapeutic principles. Clin Transl Oncol. 2012 Jun;14(6):413-22.

Tageja N, Groninger H. Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J. 2016 Jan;92(1083):34-40.

Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013 Apr;14(6):757-66.

Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, et al. The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010 Nov;335(2):362-8.

Chan A, Kim HK, Hsieh RK, Yu S, de Lima Lopes G, Jr., Su WC, et al. Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis. Support Care Cancer. 2015 Jan;23(1): 283-91.

Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011 Oct;19(10):1533-8.

Dupuis LL, Roscoe JA, Olver I, Aapro M, Molassiotis A. 2016 updated MASCC/ ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy. Support Care Cancer. 2017 Jan; 25(1):317-21.

Kamen C, Tejani MA, Chandwani K, Janelsins M, Peoples AR, Roscoe JA, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol. 2014 Jan 5;722:172-9.

National Comprehensive Cancer Network. Antiemesis (Version 2.2020) [updated 2020 Apr 23; cited 2020 June 28]. Available from: professionals/physician_gls/pdf/antiemesis.pdf.

Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016 Apr 7;374(14):1356-67.

Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT3 and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014 Jan 5;722:26-37.

Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010 Jan 25;626(2-3):193-9.

Murakami M, Hashimoto H, Yamaguchi K, Yamaguchi I, Senba S, Siraishi T. Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer. Support Care Cancer. 2014 Apr;22(4):905-9.

Goodin S, Cunningham R. 5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist. 2002; 7(5):424-36.

Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet. 2005 Feb 26-Mar 4;365(9461):801-3.

Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ. The cellular mechanisms of the antiemetic action of dexamethasone and related gluco-corticoids against vomiting. Eur J Pharmacol. 2014 Jan 5;722:48-54.

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016 Jul 14;375(2):134-42.

Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul;83(7):1369-79.

Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011 Jan;22(1):30-8.

Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006 Sep;58(3):389-462.

Darmani NA. Mechanisms of broad-spectrum antiemetic efficacy of cannabinoids against chemotherapy-induced acute and delayed vomiting. Pharmaceuticals (Basel). 2010 Sep 3;3(9):2930-55.

Morales M, Wang S-D, Diaz-Ruiz O, Hyun-Jin Jho D. Cannabinoid CB1 receptor and serotonin 3 receptor subunit A (5-HT3A) are co-expressed in GABA neurons in the rat telencephalon. J Comp Neurol. 2004 Jan 6;468(2):205-16.

Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015 Nov 12;2015(11):CD009464.

Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmaco-kinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017; 80(3):441-9.